Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.  

The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.

Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK.  Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.

Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.

We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives.  While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world.  We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."

Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation.  Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com 

Dechra Veterinary Products has launched Ketodale, an anti-inflammatory injection for cattle, horses and swine.

Ketodale contains the non-steroidal anti-inflammatory drug ketoprofen 100mg/ml.  It is indicated for use in cattle and swine for diseases associated with inflammation, pain or fever. In cattle these include respiratory diseases, mastitis, osteoarticular and muscular-skeletal disorders, such as lameness and arthritis, and to ease pain post parturition. Ketodale can be used to treat swine suffering from Mastitis Metritis Agalactia (MMA) Syndrome and respiratory tract infections. 

In horses, Ketodale is indicated for diseases affecting the osteoarticular and muscular-skeletal system associated with pain and inflammation. These include naviculitis, arthritis and laminitis. It can also be used for post-surgical inflammation and symptomatic therapy of colic and fever.

Ketodale is available in 50ml and 100ml vials.

To coincide with the product's launch, Dechra is carrying out a direct marketing campaign. Practices can take advantage of a special launch offer where they can purchase four vials and get a fifth free. The offer is available for a limited period only. 

To find out more about Ketodale, call Dechra on 01743 441 632 or visiting www.dechra.com

Merial has launched Equioxx, a new pain management product which the company says is the first COX-2 specific NSAID for horses

Traditional NSAIDs act by blocking the action of both COX-1 and COX-2 enzymes at the same time. Although COX-2 produces prostaglandins associated with both inflammation and pain, COX-1 has a pivotal role in maintaining normal physiological function, so inhibiting this enzyme may have an increased risk of side effects e.g. gastric ulceration. Merial says Equioxx is the only NSAID that is highly COX-2 selective (up to 643 times more selective for COX-2 than COX-1), acting to reduce pain and inflammation but without affecting the COX-1 enzyme at therapeutic levels.

Equioxx contains the active ingredient firocoxib, and Merial says it is proven to be effective at reducing chronic lameness in horses. Appearing in blood plasma within 30 minutes of oral dosing, its pharmacokinetic profile allows once daily dosing. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.

Equioxx is available as either a low dose injectable solution or a palatable oral paste.

For more information contact Merial Customer Services on 0870 6000 123

CEVA Animal Health has produced Understanding sacroiliac disease, a leaflet to help horse owners understand the cause, diagnosis and management of sacroiliac disease.

CEVA says sacroiliac disease can be a particular challenge because although it can occur in isolation it often occurs in addition to other sources of hindlimb lameness. Acute sacroiliac injury is usually a result of trauma, such as a fall, which may cause pelvic rotation or fracture, resulting in hindlimb lameness and sensitivity to palpation of the tubera sacrale soon after injury. With chronic sacroiliac disease there is usually no history of trauma, rather a prolonged history of poor performance.

Understanding sacroiliac disease explains the anatomy of the sacroiliac joint, the clinical signs of the disease, how it is diagnosed, the treatment options and the general prognosis. The leaflet is available to equine vet practices as a useful information source for clients. You can order free copies from your CEVA sales representative.

Horiba Medical has announced it is the official exclusive UK distributor of the fully automated Vet abc Plus+ veterinary haematology analyser from scil animal care company GmbH, Germany.

According to the company, the compact Vet abc Plus+ provides a complete blood count (CBC), including 4-part white blood cell (WBC) differential, from only 10 µl of EDTA whole blood, in only 60 seconds.

The Vet abc Plus⁺ provides pre-installed settings to analyse samples from dogs, cats, horses, rabbits, mice, rats, cattle, pigs and sheep. For dogs, cats and horses, the Vet abc Plus⁺ provides a 4-part WBC differential blood count, including a differentiation of the leucocytes to identify lymphocytes, monocytes, granulocytes and eosinophils. Results are available in 60 seconds on screen or can be automatically printed out and transferred to the practice information system or clinical notes. For ease-of-use, the Vet abc Plus+ also incorporates a self-contained reagent and waste system which provides a clean operation whilst being easy to replenish.

Borne from an existing manufacturing partnership, scil and HORIBA Medical already have over 6000 veterinary haematology analysers placed globally. Horiba says the new UK distribution agreement enables UK veterinary professionals to not only procure the Vet abc Plus+ analyser, but also receive expert service and support directly from the manufacturer HORIBA Medical and its team of UK specialists.

For more information, visit: www.horiba.com/uk/medical

BEVA President, Madeleine Campbell will be announcing plans for a veterinary-led European Transport Forum at BEVA Congress this year (8-11 September 2010), to discuss how the welfare of horses during transport can be improved through the better enforcement of legislation.

Dr Campbell is also the British Veterinary Association representative on the Federation of Veterinarians of Europe (FVE) working party for transport. The Forum, which will be held in Brussels on 29 November 2010, has been jointly organised by the FVE and BEVA and is sponsored by World Horse Welfare (WHW). It is hoped that it will be attended by over 150 participants, including representatives of EU Member States, CVOs, Members of the European Commission and European Parliament, scientific experts, national veterinary organisations, animal transport associations and animal welfare associations.

The Forum will review the enforcement of the existing European regulations that currently govern the transport of horses for slaughter and for other purposes. Areas for practical improvement will be identified with the key focus on the enforcement of current legislation and the role of vets in ensuring that the welfare of horses in transit is protected. The conference will endeavour to define the critical control points, effective control systems and good practices. It will also look into trade flows, animal health risks, horse identification and the effects of closing horse slaughterhouses.

Dr Campbell said: "It is all very well to campaign for new regulations but at present even the existing regulations are not being enforced adequately. The crux of the matter is enforcement and there are none better placed to help with this than vets. If we can all work collectively we should have the strength to make a real impact. This is what the Forum is about."

Dr Campbell will be speaking about the European Transport Forum at the Congress press conference on 10 September between 9am and 10am.

BEVA Congress runs from 8-11 September 2010 at the International Convention Centre, Birmingham. For further information and to register visit http://www.beva.org.uk/

CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.

Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.

The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.

Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.

Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.

Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.

CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/

Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial

Reference 
M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x

Dechra Veterinary Products has launched free online Fluid Therapy Calculators to help veterinary staff calculate their patients' fluid requirements.

There are two versions available, small animal and equine. Both are available as an online tool or as a download to your desktop (note that to get hold of the desktop version, you need to try out the online calculator first). 

For small animals, there are three options available. The M1/M2/M3 Plan calculates simple multiplications of the maintenance rate, while the Comprehensive Plan calculates fluid required to provide maintenance requirements, correct dehydration or replace ongoing losses. The third option, the Simple Rate Calculator, is a tool for calculating resuscitation fluid rates and can also be used for large animals. The Equine Plan calculates fluid requirements and infusion rates for both adult horses and foals.  

Dechra says it has launched the calculators as the next component of its Vetivex Fluid support package. Along with the Fluids Knowledge Programme, this initiative aims to help veterinary staff across the UK to deliver effective fluid therapy. 

Larry King, Product Manager at Dechra, said: "The calculators are a quick and easy reference tool for today's busy vet. You simply fill in the body weight and animal type, key in a few details and you have an instant but very accurate fluid rate calculated for you. It saves time and effort and ensures the animal is given the correct amount of fluid. The more effective the fluid therapy regime the faster the animal recovers."

The free Fluid Therapy Calculator is just one of a number of tools Dechra uses to support its Vetivex range of fluids.  There is a range of downloadable reference documents, charts and guides available on the website http://www.fluidtherapy.co.uk/ including the Fluid Knowledge Programme and a full CPD Programme focused on effective fluid therapy.

Intervet/Schering-Plough Animal Health has announced that it is re-introducing Equilis StrepE, the only strangles vaccine for horses in Europe. The vaccine was voluntarily withdrawn from the market in 2007 for stability reasons.

Equilis StrepE, which has already been relaunched in the Netherlands, is now scheduled to arrive in Italy in September and the United Kingdom in October this year. Further re-launches in European countries are scheduled later in 2010 and beyond.

According to Intervet/Schering-Plough, three years of additional research and development have resulted in several improvements to the vaccine, including a better manufacturing process to ensure that the product maintains its characteristics throughout its shelf-life. A more user-friendly applicator has been developed, which enables the needle to slot into place, thereby making it easier to administer the vaccine.

Equilis StrepE is administered through a submucosal injection in the upper lip of the horse and provides immunity for three months following two initial injections, four weeks apart. The vaccine significantly reduces clinical signs of strangles and occurrence of lymph node abscesses in horses that are at risk of infection.

Dr. Peter Daels, veterinarian at the Keros Insemination and Embryo Transfer Center in Beselare (Belgium) said: "In our recipient embryo transfer herd, we have used this strangles vaccine on over 500 mares. After a few applications, the vaccine was easy to administer and did not cause any serious side effects. Despite a steady flow of new horses, only eight cases of strangles were noted - all were mild and most were newly acquired horses that had apparently been exposed shortly before vaccination. I believe that the vaccine provided solid protection against the disease, reduced the severity of clinical cases and eliminated the risk of a widespread outbreak in our herd."

Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering Plough Animal Health said: "The re-launch of Equilis StrepE in Europe is an important milestone in our efforts to fully meet the needs of our customers in the equine industry. We continue to work in a very intense and comprehensive way to ensure adequate supply of our equine vaccine range". 

Alstoe Animal Health has introduced a new, palatable joint nutrient supplement for horses.

According to the company, the benefits of feeding equine joint nutrient supplements to assist with maintaining mobility and supporting health joint function has been well documented, but until now, their flavours have often had to be disguised by mixing them into the feed in an attempt to ensure compliance.

Easeflex Equine palatable pellets include alfalfa, an equine favourite which has been used in the USA for some time, and shown to be readily accepted by horses, without the need to mix with the feed.

Alstoe says Easeflex Equine contains high levels of glucosamine hydrochloride and chondroitin sulphate, which are important in the production of glycosaminoglycans, and which have chondroprotective properties that aid in the natural renewal of cartilaginous tissue. Easeflex Equine palatable pellets also include MSM (methyl-sulphonyl-methane), a source of bioavailable sulphur, a key component of connective tissue and important in the synthesis of articular cartilage. Antioxidants are also present to help prevent damage by free radicals, as well as the essential trace minerals, copper, zinc and manganese.

Easeflex Equine palatable pellets can be fed to horses, ponies and donkeys of any age. The company recommends initial daily feeding of a double loading quantity for the first four to six weeks, thereafter reducing to a maintenance level or as directed by the veterinary surgeon. The amount of pellets to be fed depends on the weight of the animal, one small scoop containing 28g of pellets can be a daily dose for a horse of up to 450kg. Easeflex Equine palatable pellets are available in 1.7kg and 4.54kg tubs.

From 1st March vets can sign up to be alerted to all recorded equine influenza cases in the UK, thanks to a new service from the Animal Health Trust (AHT) and Merial Animal Health.

Tell Tail is the UK's first equine influenza (EI) text alert service exclusively for equine vets, set up to provide practices and their clients with what could be invaluable information in the face of a potential outbreak. 

Dr Emma Batson from Merial said: "Vets will be notified of an EI outbreak within 48 hours of confirmed diagnosis. Not only will this allow them to alert their clients, but we believe that it will also help to encourage horse owners to become more compliant with vaccination schedules.

"Currently it is estimated that only a third of the UK horse population is vaccinated for EI. This situation is not only a potential welfare issue, but it also provides practices with a significant opportunity to increase the number of horses protected against EI, resulting in a win-win situation for all."

Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT, believes the text alert service will also help improve awareness and knowledge of EI, and he hopes all equine vets will sign up for the scheme. He said: "We believe that the launch of the alert service for vets marks an important step in the quest to help minimise the risk of an EI outbreak in the UK.

"EI doesn't have a carrier state, which means that it never goes away and re-emerges, instead it circulates continuously. So without continued surveillance we could easily lose track of it.

"We hope that as well as allowing practices to track and respond to outbreaks in their area, the alerts will also encourage vets to send in samples from animals with cold and flu-like symptoms. This is a free service which in turn provides us with more information to circulate within the industry, allowing everyone to be more effective at managing the disease.

"Vaccination is our best defence against EI, but to remain effective the World Organisation for Animal Health (OIE) Expert Surveillance Panel, needs to make any update recommendations based on the latest position in the field. And this information can only be gathered via effective surveillance."

Dr Batson agrees and hopes that the combination of the Tell Tail text alert service and surveillance scheme will help to reduce the risk of an outbreak occurring in the UK. She said: "In the UK we continue to see regular confirmed outbreaks of EI, so we can never afford to become complacent about the risks.

"You only have to look at the relatively recent major outbreaks in Australia, South Africa, India and China, to see the devastating effects which can ripple throughout equine industries, both in financial as well as welfare terms."

Tell Tail is a free service. To register your interest, text your name, practice and postcode to 07797 801863. Alternatively, visit http://www.merial.com/ and click on the Tell Tail link, or speak to your Merial territory manager.

The National Association of Veterinary Physiotherapists (NAVP) is calling for the Royal College of Veterinary Surgeons (RCVS) to establish an independent register of veterinary physiotherapy practitioners. According to the Association, such a register would eliminate individuals practicing without proper training and qualifications and raise the standard of veterinary physiotherapy by providing a disciplinary role.

NAVP President and leading veterinary anatomist Dr Sue Kempson is heading the NAVP campaign for the establishment of an independent register. In a letter to the President of the RCVS, Dr Kempson said: "Recognition by the veterinary profession of the role of physiotherapy in post-operative rehabilitation and in supporting both companion and performance animals is growing. However, we do believe that referring veterinary surgeons are increasingly faced with a dilemma caused by the wide differential between qualifications offered by the various organisations representing practitioners in areas such as physiotherapy. There is an urgent need for a distinction to be made between these different types of qualification. To this end, there should be a clearly defined independent register of practitioners with appropriately validated qualifications which are clearly understood by the veterinary profession."

In partnership with Harper Adams University College, the NAVP has introduced a fully-validated post-graduate course in veterinary physiotherapy which offers a choice of Post-Graduate Diploma or Masters Degree. Only one other professional body, the Association of Chartered Physiotherapists in Animal Therapy (ACPAT) currently offers a similar qualification at this level.

Dr Kempson said: "The establishment of a register of physiotherapists would greatly assist vets and their clients to make informed decisions on their choice of therapist. It would eliminate those individuals without proper training and qualifications and help raise the standard of veterinary physiotherapy by providing a disciplinary role. At present there are no sanctions on those people practicing without the necessary qualifications or those whose work is sub-standard or who are guilty of professional misconduct.

"We do not believe that such a register should rest with any individual professional body or be affiliated to specific educational courses. To have authority, it requires independence and a register held under the auspices of the Royal College of Veterinary Surgeons would carry the credibility that the veterinary profession requires."